The Rise of Drug-Resistant Gonorrhea

What does "drug-resistant" or "super" gonorrhea actually mean?

Drug-resistant gonorrhea, sometimes called "super gonorrhea" in media coverage, refers to strains of the bacteria that have evolved to survive the antibiotics normally used to treat them. Neisseria gonorrhoeae has developed resistance to nearly every class of antibiotic ever used against it, and cephalosporins — the class that includes the current recommended treatment — are now considered the last fully reliable option, which is why public health agencies classify drug-resistant gonorrhea as an urgent threat 1Ref 1Centers for Disease Control and Prevention (2024).Drug-Resistant Gonorrhea.Supports that Neisseria gonorrhoeae has developed resistance to nearly every antibiotic used to treat it, that cephalosporins are the last recommended class, and that drug-resistant gonorrhea is designated an urgent public-health threat..

Gonorrhea itself is a common bacterial infection that can affect the genitals, rectum, and throat, and it is frequently asymptomatic regardless of which site is infected 2Ref 2Centers for Disease Control and Prevention (2024).About Gonorrhea.Supports basic facts about gonorrhea: a bacterial STI that can infect the genitals, rectum, and throat and is often asymptomatic, used here as background before discussing resistance.. That combination — a bacterium prone to developing resistance, and an infection that often goes undiagnosed long enough to keep spreading — is what makes the resistance story worth paying attention to beyond the headlines.

Why does gonorrhea keep developing resistance?

Gonorrhea is a bacterial infection, and bacteria exposed to an antibiotic repeatedly across a large population get repeated opportunities to develop mutations that let them survive it — the same evolutionary pressure that produces resistance in any bacterial species, just more pronounced here than in most. Over decades, one antibiotic class after another that was once first-line treatment for gonorrhea has been retired because resistant strains became common enough to make it unreliable 1Ref 1Centers for Disease Control and Prevention (2024).Drug-Resistant Gonorrhea.Supports that Neisseria gonorrhoeae has developed resistance to nearly every antibiotic used to treat it, that cephalosporins are the last recommended class, and that drug-resistant gonorrhea is designated an urgent public-health threat..

Cephalosporins are now the last fully reliable antibiotic class recommended for gonorrhea 1Ref 1Centers for Disease Control and Prevention (2024).Drug-Resistant Gonorrhea.Supports that Neisseria gonorrhoeae has developed resistance to nearly every antibiotic used to treat it, that cephalosporins are the last recommended class, and that drug-resistant gonorrhea is designated an urgent public-health threat.. That history is part of why any single new resistant strain draws public health attention out of proportion to how many people it currently affects — it reads as a preview of what happens if cephalosporins follow the same path as the classes that came before them.

How is gonorrhea treated today, and why the regimen matters

Current guidelines call for injectable ceftriaxone as the recommended treatment for uncomplicated gonorrhea, with doxycycline typically added when a chlamydia infection has not been ruled out, since the two frequently occur together 3Ref 3St. Cyr S, Barbee L, Workowski KA, et al. (Centers for Disease Control and Prevention) (2020).Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020.Supports that injectable ceftriaxone is the current recommended treatment for gonorrhea, strengthened in 2020 in response to resistance concerns, with doxycycline added when chlamydial coinfection has not been excluded.. Guidelines strengthened this regimen in 2020 specifically in response to resistance concerns.

That update is part of why using the current guideline-recommended treatment — rather than an older regimen, a leftover prescription, or an antibiotic chosen without testing — matters more for gonorrhea than it does for many other infections. A treatment that worked reliably a decade ago is not a safe assumption for a bacterium this actively evolving.

This is also why self-treating with antibiotics left over from a previous prescription, or a different infection entirely, carries more risk with gonorrhea than it might with other conditions: the wrong antibiotic, or the right one at an inadequate regimen, does not just fail to cure the infection — it can help select for the very resistance the guidelines are trying to stay ahead of.

What happens if treatment doesn't work?

Symptoms that persist after treatment are taken seriously and usually prompt a test-of-cure — retesting to confirm the infection actually cleared — along with a review of whether a partner was treated and whether reinfection is a more likely explanation than resistance. True treatment failure from a resistant strain remains uncommon in the United States, but any confirmed case is reported to public health authorities and investigated, because tracking where resistant strains appear is how the recommended treatment stays effective for everyone else 1Ref 1Centers for Disease Control and Prevention (2024).Drug-Resistant Gonorrhea.Supports that Neisseria gonorrhoeae has developed resistance to nearly every antibiotic used to treat it, that cephalosporins are the last recommended class, and that drug-resistant gonorrhea is designated an urgent public-health threat..

When a resistant strain is confirmed, treatment typically moves to an alternative antibiotic or combination chosen with input from an infectious disease specialist, guided by lab testing that shows which antibiotics the specific strain still responds to, rather than trial and error.

Where doxy-PEP fits into the resistance conversation

Doxy-PEP — a course of doxycycline started after sex to reduce the risk of a bacterial STI — is recommended for certain groups at high risk of repeated bacterial STIs, and it has been shown to meaningfully lower rates of chlamydia and syphilis, with a smaller effect against gonorrhea specifically 5Ref 5Bachmann LH, Barbee LA, Chan P, et al. (Centers for Disease Control and Prevention) (2024).CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.Supports the 2024 CDC doxy-PEP guideline recommending doxycycline after sex for MSM and transgender women with a recent bacterial STI, with STI testing every 3-6 months, used here to explain the resistance tension around repeated antibiotic exposure.. Because it involves regular antibiotic exposure in the same population already being watched for resistance, doxy-pep resistance concerns are part of the ongoing conversation about how to use the strategy without accelerating the same problem it is meant to help prevent.

That tension doesn't cancel out the benefit for the people it's recommended for, but it is why doxy-PEP comes with a recommendation for STI testing every few months rather than being treated as a standalone fix, and why it isn't recommended universally for anyone sexually active.

Why screening still matters more, not less

Sexually active women 24 and younger are recommended for chlamydia and gonorrhea screening at least annually, with more frequent screening recommended for men who have sex with men and others at ongoing risk 4Ref 4US Preventive Services Task Force (2021).Chlamydia and Gonorrhea: Screening.Supports the recommendation to screen sexually active women 24 and younger for gonorrhea, used here to explain why ongoing screening matters for controlling resistant strains at a population level.. Those recommendations matter just as much in a resistant-strain era as before — catching and treating an infection promptly with the current effective regimen is what keeps the broader population of circulating gonorrhea responsive to that regimen in the first place.

More than 600,000 gonorrhea cases were reported in the United States in 2023 alone 6Ref 6Centers for Disease Control and Prevention (2025).National Overview of STIs in 2023.Supports that more than 600,000 gonorrhea cases were reported in the United States in 2023, used here to give scale to the population affected by treatment and resistance patterns., a scale that makes even a small percentage of resistant cases a meaningful number of people, and a reminder that individual testing and treatment choices add up to the population-level resistance picture over time.

What this means if you're diagnosed with gonorrhea today

For almost everyone diagnosed with gonorrhea today, the current recommended treatment still works, and a resistant strain remains the exception rather than the expectation. Completing the full treatment as prescribed, avoiding sex until treatment is finished and symptoms have resolved, and getting a partner treated are still the actions that matter most for any individual case, resistant strain or not.

Symptoms that don't improve within about a week of treatment are worth reporting back to a clinician rather than assuming the infection is simply taking its time to clear, since that pattern is exactly what prompts a test-of-cure and closer follow-up.